227 related articles for article (PubMed ID: 18226321)
1. Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: a case report and systematic review.
Wojtowicz JM; Yarema MC; Wax PM
CJEM; 2008 Jan; 10(1):69-74. PubMed ID: 18226321
[TBL] [Abstract][Full Text] [Related]
2. Acute toxicity and withdrawal syndromes related to γ-hydroxybutyrate (GHB) and its analogues γ-butyrolactone (GBL) and 1,4-butanediol (1,4-BD).
Wood DM; Brailsford AD; Dargan PI
Drug Test Anal; 2011; 3(7-8):417-25. PubMed ID: 21548140
[TBL] [Abstract][Full Text] [Related]
3. The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol.
Schep LJ; Knudsen K; Slaughter RJ; Vale JA; Mégarbane B
Clin Toxicol (Phila); 2012 Jul; 50(6):458-70. PubMed ID: 22746383
[TBL] [Abstract][Full Text] [Related]
4. Gamma-butyrolactone and 1,4-butanediol: abused analogues of gamma-hydroxybutyrate.
Palmer RB
Toxicol Rev; 2004; 23(1):21-31. PubMed ID: 15298490
[TBL] [Abstract][Full Text] [Related]
5. [Withdrawal syndrome after abuse of GHB (Gamma-Hydroxybutyrate) and its physiological precursors - its relevance for child and adolescent psychiatrists].
Zepf FD; Holtmann M; Duketis E; Maier J; Radeloff D; Schirman S; Wagner A; Poustka F; Wöckel L
Z Kinder Jugendpsychiatr Psychother; 2009 Sep; 37(5):413-20. PubMed ID: 19739059
[TBL] [Abstract][Full Text] [Related]
6. Consequences of 1,4-Butanediol Misuse: A Review.
Skryabin V; Shevtsova Y; Novoselova EA
Psychopharmacol Bull; 2023 Dec; 53(4):48-53. PubMed ID: 38076667
[TBL] [Abstract][Full Text] [Related]
7. Gamma hydroxybutyrate (GHB) and gamma butyrolactone (GBL) withdrawal: five case studies.
McDaniel CH; Miotto KA
J Psychoactive Drugs; 2001; 33(2):143-9. PubMed ID: 11476261
[TBL] [Abstract][Full Text] [Related]
8. The behavioural profile of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol in humans.
Bosch OG; Seifritz E
Brain Res Bull; 2016 Sep; 126(Pt 1):47-60. PubMed ID: 26855327
[TBL] [Abstract][Full Text] [Related]
9. [GHB--dangerous, addictive and uncontrollable "party drug"].
Persson SA; Eriksson A; Hallgren N; Eklund A; Berkowicz A; Druid H
Lakartidningen; 2001 Sep; 98(38):4026-31, 4033-5. PubMed ID: 11602959
[TBL] [Abstract][Full Text] [Related]
10. Gamma hydroxybutyrate (GHB), gamma butyrolactone (GBL) and 1,4-butanediol (1,4-BD; BDO): A literature review with a focus on UK fatalities related to non-medical use.
Corkery JM; Loi B; Claridge H; Goodair C; Corazza O; Elliott S; Schifano F
Neurosci Biobehav Rev; 2015 Jun; 53():52-78. PubMed ID: 25843781
[TBL] [Abstract][Full Text] [Related]
11. Evaluation for the withdrawal syndrome from gamma-hydroxybutyric acid (GHB), gamma-butyrolactone (GBL), and 1,4-butanediol (1,4-BD) in different rat lines.
Quang LS; Colombo G; Lobina C; Maccioni P; Orru A; Gessa GL; Maher TJ; Carai MA
Ann N Y Acad Sci; 2006 Aug; 1074():545-58. PubMed ID: 17105952
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological Treatment in γ-Hydroxybutyrate (GHB) and γ-Butyrolactone (GBL) Dependence: Detoxification and Relapse Prevention.
Kamal RM; van Noorden MS; Wannet W; Beurmanjer H; Dijkstra BA; Schellekens A
CNS Drugs; 2017 Jan; 31(1):51-64. PubMed ID: 28004314
[TBL] [Abstract][Full Text] [Related]
13. Inpatient management of GHB/GBL withdrawal.
Delic M
Psychiatr Danub; 2019 Sep; 31(Suppl 3):354-356. PubMed ID: 31488752
[TBL] [Abstract][Full Text] [Related]
14. The gamma-hydroxybutyrate withdrawal syndrome.
Tarabar AF; Nelson LS
Toxicol Rev; 2004; 23(1):45-9. PubMed ID: 15298492
[TBL] [Abstract][Full Text] [Related]
15. Gamma-hydroxybutyrate withdrawal syndrome.
Dyer JE; Roth B; Hyma BA
Ann Emerg Med; 2001 Feb; 37(2):147-53. PubMed ID: 11174231
[TBL] [Abstract][Full Text] [Related]
16. Pentobarbital for severe gamma-butyrolactone withdrawal.
Sivilotti ML; Burns MJ; Aaron CK; Greenberg MJ
Ann Emerg Med; 2001 Dec; 38(6):660-5. PubMed ID: 11719746
[TBL] [Abstract][Full Text] [Related]
17. Adverse events, including death, associated with the use of 1,4-butanediol.
Zvosec DL; Smith SW; McCutcheon JR; Spillane J; Hall BJ; Peacock EA
N Engl J Med; 2001 Jan; 344(2):87-94. PubMed ID: 11150358
[TBL] [Abstract][Full Text] [Related]
18. Behavioral effects and pharmacokinetics of gamma-hydroxybutyrate (GHB) precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) in baboons.
Goodwin AK; Brown PR; Jansen EE; Jakobs C; Gibson KM; Weerts EM
Psychopharmacology (Berl); 2009 Jun; 204(3):465-76. PubMed ID: 19198808
[TBL] [Abstract][Full Text] [Related]
19. Psychiatric aspects of acute withdrawal from gamma-hydroxybutyrate (GHB) and its analogue gamma-butyrolactone (GBL): implications for psychiatry services in the general hospital.
Choudhuri D; Cross S; Dargan PI; Wood DM; Ranjith G
Int J Psychiatry Clin Pract; 2013 Jun; 17(2):154-6. PubMed ID: 23485126
[TBL] [Abstract][Full Text] [Related]
20. Gamma-hydroxybutyrate (GHB), 1,4-butanediol (1,4BD), and gamma-butyrolactone (GBL) intoxication: A state-of-the-art review.
Dufayet L; Bargel S; Bonnet A; Boukerma AK; Chevallier C; Evrard M; Guillotin S; Loeuillet E; Paradis C; Pouget AM; Reynoard J; Vaucel JA
Regul Toxicol Pharmacol; 2023 Aug; 142():105435. PubMed ID: 37343712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
